Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan 1;20(4):743-62.
doi: 10.2741/4334.

Rational clinical trial design for antibody mediated renal allograft injury

Shaifali Sandal  1 , Martin S Zand  1
Affiliations
Review

Rational clinical trial design for antibody mediated renal allograft injury

Shaifali Sandal et al. Front Biosci (Landmark Ed). .

Abstract

Antibody mediated renal allograft rejection is a significant cause of acute and chronic graft loss. Recent work has revealed that AMR is a complex processes, involving B and plasma cells, donor-specific antibodies, complement, vascular endothelial cells, NK cells, Fc receptors, cytokines and chemokines. These insights have led to the development of numerous new therapies, and adaptation of others originally developed for treatment of hemetologic malignancies, autoimmune and complement mediated conditions. Here we review emerging insights into the pathophysiology of AMR as well as current and emerging therapies for both acute and chronic AMR. Finally, we discuss rational clinical trial design in light of antibody and B cell immunobiology, as well as appropriate efficacy metrics to identify robust protocols and therapeutic agents.

PubMed Disclaimer

References

    1. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. 2010;363(15):1451–62. - PubMed
    1. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM, 3rd, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, Zeevi A. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010;10(3):464–71. - PubMed
    1. Dragun D, Philippe A, Catar R. Role of non-HLA antibodies in organ transplantation. Curr Opin Organ Transplant. 2012;17(4):440–5. - PubMed
    1. Luo L, Li Z, Wu W, Luo G, Xu C, Sun Z, Mei H. Role of MICA antibodies in solid organ transplantation. Clin Transplant. 2013 - PubMed
    1. Sapak M, Chrenova S, Tirpakova J, Zilinska Z, Durmanova V, Shawkatova I, Jakus V, Kuba D, Buc M. Donor non-specific MICA antibodies in renal transplant recipients. Immunobiology. 2013 - PubMed

Publication types

MeSH terms